Our Mission
Discover & engineer intelligent treatments for our companionsco-pilotscare-takers

We accelerate the development of new medicines, so the pets we love can lead happier and healthier lives.

Proven Leaders

We've built startups, climbed the ladder in Fortune 100, and everything in between

Solving Unmet Needs

We focus exclusively on solving the unmet needs of the animal health community

Advanced Technology

We use software end-to-end to accelerate drug development

We find solutions for veterinary therapeutics.
LAVERDIA-CA1, The first approved targeted oral treatment for lymphoma in dogs.
Anivive is also in the final stages of pursuing USDA conditional licensure for an anti-fungal vaccine, which will be the first anti-fungal vaccine ever approved for any species.

Investors

Bookmark our new investor relations section to see timely business updates and the latest accounting reports from our CFO.

Anivive is led by a seasoned mix of entrepreneurs, pet industry executives, and software innovators.

85+ FDA

approvals (CVM NADA)

1,200+

animal studies overseen

650+

peer reviewed publications

$1B+

annual direct-to-vet sales